Use of skin biomarker profiles to distinguish Schnitzler syndrome from chronic spontaneous urticaria: results of a pilot study

Bonnekoh, Hanna; Maurer, Marcus; Krause, Karoline

doi:10.1111/bjd.15705

Cited by 24 publications

(24 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our studies confirmed the upregulation of IL‐1‐related cytokines (IL‐1β, IL‐6, and IL‐18) compared to CSU patients and healthy controls and production of IL‐1β as well as IL‐6 by MCs in SchS skin. Interestingly, we observed a non‐significant trend towards elevated dermal MC numbers in SchS . Likewise, we found higher expression of inflammasome components (ASC and caspase‐1) in the lesional skin of SchS as evidence of cutaneous NLRP3 activation and suggested using these as a skin biomarker profile differentiating SchS from CSU.…”

Section: Mast Cells In Autoinflammatory Diseasesmentioning

confidence: 60%

“…Interestingly, antimicrobial peptides (AMPs) were demonstrated to be highly upregulated in lesional skin of SchS and their expression in keratinocytes could be induced by TLR3 agonist poly:IC, IL‐1β and IL‐17. It was therefore hypothesized that keratinocyte AMPs can be induced via IL‐1β produced by MCs and neutrophil‐derived IL‐17 whereby AMPs contribute via leukocyte chemotaxis to the skin inflammation which has its morphologic correlate in the neutrophil‐dominated urticarial dermatosis . Still, it remains unclear what exactly drives the cutaneous inflammasome activation and how the different cellular players interact to generate the urticarial rash in SchS patients.…”

Section: Mast Cells In Autoinflammatory Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

The role of mast cells in autoinflammation

Bonnekoh

Kambe

Krause

2018

Immunological Reviews

View full text Add to dashboard Cite

The concept of autoinflammation was proposed to define a new class of immune disorders categorized by self-directed inflammation that is driven via activation of innate immune pathways. Within innate immunity, inflammasomes serve as intracellular signaling platforms to endogenous danger molecules and pathogens. Their key function is the cleavage of pro-interleukin-1β (pro-IL-1β) into its active form to promote inflammation and programmed cell death. A growing number of inflammasome sensors were described, among which NLR family pyrin domain containing 3 (NLRP3) is the best-studied sensor. Besides macrophages, monocytes, and other innate immune cells, mast cells (MCs) were shown to express functional inflammasomes too. Also, MCs are both, a source and target of IL-1β. Here we review the functional relevance and role of MC inflammasomes and MC-derived IL-1β in contributing to the inflammation at the skin, joints, and central nervous system in rare monogenic autoinflammatory conditions and also common inflammatory and degenerative diseases.

show abstract

Section: Mast Cells In Autoinflammatory Diseasesmentioning

confidence: 60%

Section: Mast Cells In Autoinflammatory Diseasesmentioning

confidence: 99%

The role of mast cells in autoinflammation

Bonnekoh

Kambe

Krause

2018

Immunological Reviews

View full text Add to dashboard Cite

show abstract

“…The set of parameters was chosen based on known alterations in other chronic inflammatory diseases with both skin and joint involvement, such as psoriasis and hidradenitis suppurativa . It also included IL‐6 and IL‐1β, known to be elevated locally and/or systemically in SchS . In this analysis, the chemoattractant CCL2 (also known as monocyte chemoattractant protein 1) turned out to be clearly elevated in patients with SchS compared with controls (Fig.…”

Section: Resultsmentioning

confidence: 99%

Association of CCL2 with systemic inflammation in Schnitzler syndrome

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Important differential diagnoses of CSU include autoinflammatory syndromes such as Schnitzler syndrome and urticarial vasculitis (Figure ). While these two disorders are likewise characterized by wheals, unlike CSU, these are mediated by interleukin 1 and not by histamine . It is therefore important to identify these differential diagnoses in order to initiate effective treatment.…”

Section: Diagnostic Approach To Chronic Spontaneous Urticariamentioning

confidence: 99%

Chronic urticaria – What does the new guideline tell us?

Maurer

Zuberbier

Siebenhaar

et al. 2018

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Patients with chronic urticaria experience significant impairment, and require an effective treatment. Such treatment is preceded by a thorough diagnostic workup and measurement of disease activity, disease burden and disease control using well--established tools. Treatment is subsequently adjusted according to patient needs and therapeutic response, based on the tenet "as much as necessary, as little as possible" (in that order). Once disease control has been achieved, it is recommended that intermittent attempts at medication withdrawal be made in order to identify spontaneous disease remission. Chronic urticaria should be treated until spontaneous remission occurs.

show abstract

Use of skin biomarker profiles to distinguish Schnitzler syndrome from chronic spontaneous urticaria: results of a pilot study

Cited by 24 publications

References 10 publications

The role of mast cells in autoinflammation

The role of mast cells in autoinflammation

Association of CCL2 with systemic inflammation in Schnitzler syndrome

Chronic urticaria – What does the new guideline tell us?

Contact Info

Product

Resources

About